Double‐masked, placebo‐controlled evaluation of loteprednol etabonate 0.5 for postoperative inflammation

@article{Stewart1998DoublemaskedPE,
  title={Double‐masked, placebo‐controlled evaluation of loteprednol etabonate 0.5 for postoperative inflammation},
  author={Robert Stewart and B L Horwitz and John F. Howes and Gary D. Novack and K Hart},
  journal={Journal of Cataract and Refractive Surgery},
  year={1998},
  volume={24},
  pages={1480–1489}
}
Purpose: To compare the efficacy and safety of loteprednol etabonate 0.5% with those of a placebo (vehicle) in controlling anterior chamber cell and flare reaction in patients having cataract surgery with intraocular lens (IOL) implantation. Methods: This randomized, double‐masked, placebo‐controlled, parallel‐group multicenter study comprised patients who exhibited a minimum anterior chamber inflammation (ACI) score (sum of cell and flare reaction) of 3 (0 to 9 scale) on the day after cataract… 
Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery
TLDR
Loteprednol etabonate gel 0.5% was efficacious and safe in treating postoperative inflammation and pain in patients with anterior chamber cell grade 2 or higher after cataract surgery.
Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
TLDR
LE ointment was efficacious and well tolerated in the treatment of ocular inflammation and pain following cataract surgery and Visual acuity and dilated funduscopy results were similar between the treatment groups, with the exception of visual acuity at visits 5 and 6, which favored LE ointments.
Loteprednol Etabonate Ophthalmic Gel 0.5% Following Cataract Surgery: Integrated Analysis of Two Clinical Studies
TLDR
LE gel 0.5% was efficacious and well tolerated in the treatment of postoperative pain and inflammation following ocular surgery, with minimal risk of IOP elevation.
Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial
TLDR
LE gel 0.5% was efficacious and safe in treating postoperative inflammation and pain in this clinical study and mean IOP decreased in both treatment groups; one patient in the LE group demonstrated a clinically significant increase in IOP that was not considered drug-related.
A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.
TLDR
Loteprednol etabonate 0.2% was more effective than placebo in the treatment of seasonal allergic conjunctivitis and had a safety profile comparable to placebo.
Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery
TLDR
Equivalency was achieved between the 2 treatment groups with no significant differences throughout the 3‐week follow-up, and there was less fluctuation in IOP assessments in patients treated with loteprednol etabonate than in patientstreated with prednisolone acetate.
Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group.
TLDR
Although a clinically meaningful reduction of signs and symptoms was noted in both treatment groups, loteprednol etabonate was less effective than prednisolone acetate in both of these controlled studies.
A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
TLDR
These real-world data suggest that canaloplasty with or without cataract surgery managed postoperatively with LE suspension 0.5% is effective and safe in the glaucoma patient.
Prospective Randomized Trial Comparing Efficacy of Topical Loteprednol Etabonate 0.5% Versus Cyclosporine-A 0.05% for Treatment of Dry Eye Syndrome Following Hematopoietic Stem Cell Transplantation
TLDR
Pre-HSCT initiation of LE 0.5% appears to be safe and may be as effective as CsA 0.05% for the treatment and prophylaxis of dry eye syndrome after hematopoietic stem cell transplantation (HSCT).
Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery
TLDR
KPI-121 1% ophthalmic suspension was effective in resolving postoperative ocular inflammation and pain when dosed BID for 2 weeks in patients following cataract surgery and found to be safe and well tolerated in both trials.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 23 REFERENCES
A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.
  • P. Asbell, J. Howes
  • Medicine
    The CLAO journal : official publication of the Contact Lens Association of Ophthalmologists, Inc
  • 1997
TLDR
The rapid therapeutic response, combined with the low incidence, late development, and transient nature of any IOP elevation suggests that LE may be helpful in treating GPC.
The effect of ketorolac tromethamine solution 0.5% in reducing postoperative inflammation after cataract extraction and intraocular lens implantation.
TLDR
This study supported previous studies that suggested ketorolac tromethamine ophthalmic solution 0.5% was effective and safe as a nonsteroidal anti-inflammatory agent for topical use after ECCE and IOL implantation.
A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.
TLDR
Loteprednol etabonate is generally effective in prophylaxis of seasonal allergic conjunctivitis and has an acceptable safety profile.
Ketorolac, prednisolone, and dexamethasone for postoperative inflammation.
This 6-week, partially masked, three-arm, multicenter study was conducted to evaluate the postoperative anti-inflammatory efficacy of ketorolac, a cyclooxygenase inhibitor. The study setting was the
Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspension
TLDR
Rimexolone 1 % ophthalmic suspension was safe and significantly more effective than a placebo in controlling intraocular inflammation after cataract extraction when used four times daily and continued for 2 weeks.
Reduction of inflammation following cataract surgery by the nonsteroidal anti-inflammatory drug, flurbiprofen.
TLDR
Treatment with flurbiprofen appeared to decrease the severity of inflammation following cataract extraction surgery.
The effect of ketorolac tromethamine in reducing postoperative inflammation: double-mask parallel comparison with dexamethasone.
TLDR
Kentorolac solution was as effective as dexamethasone solution in suppressing postoperative inflammation after cataract surgery as measured by fluorophotometry and as observed by slit-lamp examinations.
Dexamethasone versus diclofenac sodium eyedrops to treat inflammation after cataract surgery
TLDR
Diclofenac sodium seems to be as potent as dexamethasone phosphate, as good an anti‐inflammatory agent, and may replace corticosteroid therapy after cataract surgery.
Pretreatment with topical diclofenac sodium to decrease postoperative inflammation.
TLDR
The pretreatment with an NSAID before cataract surgery can reduce the amount of initial postoperative inflammation.
The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on postsurgical blood-aqueous barrier.
TLDR
It is suggested that ketorolac ophthalmic solution may be effective and safe as a nonsteroidal anti-inflammatory agent for topical use after cataract surgery and intraocular lens implantation in place of topically administered corticosteroids.
...
1
2
3
...